270
Participants
Start Date
February 28, 2005
Primary Completion Date
December 31, 2006
Study Completion Date
December 31, 2006
Tesaglitazar
0.5 in combination with insulin (with or without other oral antidiabetic drugs)
Research Site, Birmingham
Research Site, Phoenix
Research Site, Tucson
Research Site, Fresno
Research Site, Greenbrae
Research Site, La Jolla
Research Site, Northridge
Research Site, Riverside
Research Site, San Diego
Research Site, Santa Monica
Research Site, Spring Valley
Research Site, Walnut Creek
Research Site, West Hills
Research Site, Waterbury
Research Site, Washington D.C.
Research Site, Gainesville
Research Site, Hollywood
Research Site, Jacksonville
Research Site, Miami
Research Site, Orlando
Research Site, Palm Harbor
Research Site, West Palm Beach
Research Site, Augusta
Research Site, Dunwoody
Research Site, Boise
Research Site, Chicago
Research Site, Chicago Heights
Research Site, Gurnee
Research Site, Springfield
Research Site, Indianapolis
Research Site, Wichita
Research Site, New Orleans
Research Site, Baltimore
Research Site, Cadillac
Research Site, Richmond Heights
Research Site, St Louis
Research Site, Omaha
Research Site, North Las Vegas
Research Site, Pahrump
Research Site, Dover
Research Site, Albuquerque
Research Site, Brooklyn
Research Site, New Hyde Park
Research Site, Charlotte
Research Site, Wilmington
Research Site, Cincinnati
Research Site, Kettering
Research Site, Toledo
Research Site, Oklahoma City
Research Site, Medford
Research Site, Portland
Research Site, Altoona
Research Site, Cheswick
Research Site, Erie
Research Site, Philadelphia
Research Site, Columbia
Research Site, Greer
Research Site, Corpus Christi
Research Site, Dallas
Research Site, Fort Worth
Research Site, Houston
Research Site, Roseland
Research Site, San Antonio
Research Site, Richmond
Research Site, Bellevue
Research Site, Renton
Research Site, Spokane
Research Site, Tacoma
Research Site, Madison
Lead Sponsor
AstraZeneca
INDUSTRY